While I think Flaskworks is clearly a top priority for commercialization, the complexity may necessitate approval first with the current manufacturing process. They are not doing profound genetic reprogramming or manipulation of cells to the degree of Car-T, they are taking autologous dendritic cells, exposing them to lysate in highly controlled circumstances, purifying the resulting cells, and then delivering them into a state and form to be properly cryogenically frozen. Not simple, but not the same sort of complexity as many other cell therapies doing much more complex cellular manipulations.
I think their aim is to get to approvals asap, and then focus on scale-up. I do think they are simultaneously seeking approval for their process with Flaskworks, I simply do not think it is going to hold them up.